Observational obesity patients report significantly lower quality of life than semaglutide trial participants, validating IWQOL-Lite-CT for real-world use.
Background
Accurate measurement of patient-reported outcomes (PROs) is crucial in obesity research to understand the full impact of weight on daily life. The Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) is a specialized instrument designed for this purpose. However, it's important to ensure such tools perform consistently and reliably across different research settings, particularly when comparing data from highly controlled clinical trials with more heterogeneous observational studies. Understanding these differences helps interpret real-world evidence and generalize findings effectively, addressing a gap in how QoL data is contextualized.
Study Design
Researchers compared baseline IWQOL-Lite-CT scores between two distinct adult populations with a body mass index (BMI) ≥ 30: participants in a US longitudinal survey (an observational study) and those in the multinational phase 3a STEP 1 clinical trial of subcutaneous semaglutide 2.4 mg for weight management. Analyses of covariance (ANCOVA) adjusted for BMI, age, and sex were used to compare IWQOL-Lite-CT Total, Physical, Physical Function, and Psychosocial composite scores. Additionally, psychometric properties of the IWQOL-Lite-CT composite scores were evaluated using data from the longitudinal survey.
Results
After adjusting for BMI, age, and sex, participants in the longitudinal survey consistently scored lower on the IWQOL-Lite-CT at baseline compared to STEP 1 clinical trial participants. The average differences were substantial: 23.4 points lower on the IWQOL-Lite-CT Total score, 20.7 points lower on the Physical composite, 20.3 points lower on the Physical Function composite, and 24.8 points lower on the Psychosocial composite. These differences indicate a more limited weight-related functioning in the observational cohort. The psychometric evaluation confirmed the internal consistency, test-retest reliability, and construct validity of the IWQOL-Lite-CT composite scores within the longitudinal survey data. However, responsiveness analyses, which assess the instrument's ability to detect changes, were limited by small changes in weight observed in the survey population.
US individuals with obesity in a longitudinal survey exhibited significantly more limited weight-related functioning than participants in the semaglutide 2.4 mg STEP 1 clinical trial.
Key Findings
- Longitudinal survey participants scored 23.4 points lower on IWQOL-Lite-CT Total score than STEP 1 participants.
- Observational cohort showed 20.7 points lower Physical composite scores compared to clinical trial participants.
- Psychosocial composite scores were 24.8 points lower in the longitudinal survey group.
- IWQOL-Lite-CT demonstrated confirmed internal consistency, test-retest reliability, and construct validity in observational research.
Why It Matters
This study provides crucial context for interpreting patient-reported outcomes in obesity research, highlighting that observational cohorts may represent a population with a higher baseline burden of disease and lower quality of life compared to those enrolled in clinical trials. The IWQOL-Lite-CT is validated for use in observational research, enabling more robust real-world evidence generation. For clinicians and researchers, this means QoL data from different study types should be interpreted with an understanding of potential baseline differences in patient populations. This validation supports broader application of the IWQOL-Lite-CT, improving our ability to track the impact of obesity and interventions beyond controlled trial settings, informing future protocol development and patient selection strategies.
obesity
quality-of-life
iwqol-lite-ct
semaglutide
observational-study
psychometrics